Replies to post #176961 on Biotech Values

[Swick984]

QURE - Baxter was a previously partner with Chatham Therapeutics on their Hemophilia treatments and had previously paid $25 million to Chatham related to the development of those treatments. I assume their relationship was a driving factor to the eventual purchase.